Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
For the full year FY25, net profit soared 12x to Rs 345 crore
Subscribe To Our Newsletter & Stay Updated
